로봇 방사선 치료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Robotic Radiotherapy Market Summary

The global robotic radiotherapy market size was valued at USD 1.37 billion in 2024 and is projected to reach USD 3.30 billion by 2033, growing at a CAGR of 10.36% from 2025 to 2033. The industry is primarily driven by the rising prevalence of cancer worldwide, the growing demand for highly precise and minimally invasive treatment options, advancements in image-guided and robot-assisted radiotherapy technologies and increasing adoption of personalized medicine approaches.

The healthcare infrastructure expansion in emerging markets, favorable reimbursement policies in developed regions, and the ability of robotic systems to reduce treatment times and improve patient outcomes further accelerate market growth.

The increasing prevalence of cancer cases is a key factor driving the market's growth. According to the WHO article published in February 2024, Global cancer cases are projected to exceed 35 million by 2050, representing a 77% increase from the 20 million cases reported in 2022. This sharp rise fuels the need for exact and efficient treatment options, driving stronger adoption of robotic radiotherapy systems. With growing patient volumes and increasing treatment complexity, robotic platforms are becoming essential due to their accuracy, automation, and ability to minimize damage to healthy tissues.

According to the American Cancer Society, in collaboration with IARC, there were about 20 million new cancer diagnoses in 2022 and 9.7 million cancer-related deaths. These data highlight the enormous and growing demand for healthcare systems globally. This escalating cancer burden fuels the adoption of robotic radiotherapy, as such platforms offer high-precision, minimally invasive treatments that can spare healthy tissue, reduce toxicity, and support efficient, automated workflows.

The increasing adoption of incision-free oncology treatment platforms is driving growth in the robotic radiotherapy market. For example, in August 2024, Apollo Cancer Centre in Bengaluru adopted the CyberKnife S7 FIM platform, reflecting the growing shift toward robotics-enabled radiosurgery capable of treating tumors across multiple regions of the body without incisions. Similarly, Tampa General Hospital introduced its upgraded CyberKnife S7 system in January 2024, highlighting the move toward outpatient-friendly radiation therapy delivered in significantly fewer sessions. These developments demonstrate how healthcare providers are prioritizing advanced robotic systems to enhance treatment accuracy, reduce session times, and improve patient convenience. The ability to deliver highly focused radiation in just a few outpatient visits allows patients to return home the same day or next, reinforcing the demand for precise, minimally invasive therapies that streamline oncology workflows.

Several developed markets are adopting supportive reimbursement policies for advanced radiotherapy. For instance, in the US, insurance coverage increasingly includes AI-driven robotic and stereotactic radiotherapy procedures. Policy incentives promote outpatient, precise cancer therapies, encouraging hospitals to invest in these high-tech platforms. Recent updates in states such as Arizona (effective August 2025) include reimbursement rules emphasizing radiation therapy management and dosimetry services critical to adaptive therapy, supporting advanced treatment adoption. These incentives help accelerate robotic radiotherapy penetration at oncologic centers by offsetting technology costs and encouraging precision care.

The industry has attracted significant investment, reflecting strong confidence in AI-powered, adaptive, and patient-centric treatment technologies. Funding is driving innovation in real-time imaging, adaptive treatment planning, and robotic delivery, enabling improved tumor targeting, workflow efficiency, and minimally invasive, outpatient-friendly therapies. Overall, this investment activity underscores growing investor confidence in technologies that enhance clinical outcomes and accelerate the adoption of advanced robotic radiotherapy worldwide.

Global Robotic Radiotherapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global robotic radiotherapy market report based on product, technology, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Radiotherapy Systems
• Software
• 3D Cameras (Surface-Guided)
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Linear Accelerators
• Conventional Linear Accelerators
• MRI - Linear Accelerators
• Stereotactic Radiation Therapy Systems
• CyberKnife
• Gamma Knife
• Particle Therapy
• Proton Beam Therapy
• Heavy Ion Beam Therapy
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Head & Neck Cancer
• Colorectal Cancer
• Other Cancers
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Independent Radiotherapy Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Spain
  • Italy
  • France
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Application outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Robotic Radiotherapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising global cancer prevalence
    • 3.2.1.2. Increasing adoption of incision-free oncology treatment platforms
    • 3.2.1.3. Rising shift toward outpatient robotic radiation therapy solutions
    • 3.2.1.4. Technological advancements in imaging and motion tracking
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of robotic radiotherapy systems and maintenance
    • 3.2.2.2. Lack of skilled professionals to operate advanced robotic systems
• 3.3. Robotic Radiotherapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Regulatory Framework
• 3.5. Investment and Funding Landscape
• 3.6. Technology Trend Analysis
• 3.7. Case Study Analysis

Chapter 4. Robotic Radiotherapy Market Segment Analysis, By Product, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Robotic Radiotherapy Market, by Product, 2021 to 2033
• 4.5. Radiotherapy Systems
  • 4.5.1. Radiotherapy systems market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Software
  • 4.6.1. Software market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. 3D Cameras (Surface-Guided)
  • 4.7.1. 3D cameras (surface-guided) market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Robotic Radiotherapy Market Segment Analysis, By Technology, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Technology Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Robotic Radiotherapy Market, by Technology, 2021 to 2033
• 5.5. Linear Accelerators
  • 5.5.1. Linear accelerators market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Conventional Linear Accelerators
  • 5.6.1. Conventional linear accelerators market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. MRI - Linear Accelerators
  • 5.7.1. MRI - linear accelerators market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.8. Stereotactic Radiation Therapy Systems
  • 5.8.1. Stereotactic radiation therapy systems market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.9. CyberKnife
  • 5.9.1. CyberKnife market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.10. Gamma Knife
  • 5.10.1. Gamma knife market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.11. Particle Therapy
  • 5.11.1. Particle therapy market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.12. Proton Beam Therapy
  • 5.12.1. Proton beam therapy market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.13. Heavy Ion Beam Therapy
  • 5.13.1. Heavy ion beam therapy market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Robotic Radiotherapy Market Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. Application Market Share Analysis, 2024 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Robotic Radiotherapy Market, by Application, 2021 to 2033
• 6.5. Prostate Cancer
  • 6.5.1. Prostate cancer market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Breast Cancer
  • 6.6.1. Breast cancer market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Lung Cancer
  • 6.7.1. Lung cancer market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.8. Head & Neck Cancer
  • 6.8.1. Head & neck cancer market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.9. Colorectal Cancer
  • 6.9.1. Colorectal cancer market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.10. Other Cancers
  • 6.10.1. Other cancers market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Robotic Radiotherapy Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

• 7.1. Definition and Scope
• 7.2. End Use Market Share Analysis, 2024 & 2033
• 7.3. Segment Dashboard
• 7.4. Global Robotic Radiotherapy Market, by End Use, 2021 to 2033
• 7.5. Hospitals
  • 7.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD million)
• 7.6. Independent Radiotherapy Centers
  • 7.6.1. Independent radiotherapy centers market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Robotic Radiotherapy Market Segment Analysis, By Region, By Product, By Technology, By Application, By End Use, 2021 - 2033 (USD Million)

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Regional Market Snapshot
• 8.4. Robotic Radiotherapy Market Share by Region, 2024 & 2033:
• 8.5. North America
  • 8.5.1. North America robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory Scenario
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. U.S. robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory Scenario
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Canada robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory Scenario
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Mexico robotic radiotherapy market, 2021 - 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory Scenario
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. UK robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Germany robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory Scenario
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. France robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory Scenario
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Italy robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory Scenario
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Spain robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory Scenario
    • 8.6.7.3. Competitive Scenario
    • 8.6.7.4. Norway robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory Scenario
    • 8.6.8.3. Competitive Scenario
    • 8.6.8.4. Sweden robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory Scenario
    • 8.6.9.3. Competitive Scenario
    • 8.6.9.4. Denmark robotic radiotherapy market, 2021 - 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory Scenario
    • 8.7.1.3. Competitive Scenario
    • 8.7.1.4. Japan robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory Scenario
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. China robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory Scenario
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. India robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory Scenario
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Australia robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory Scenario
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. South Korea robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory Scenario
    • 8.7.6.3. Competitive Scenario
    • 8.7.6.4. Thailand robotic radiotherapy market, 2021 - 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory Scenario
    • 8.8.1.3. Competitive Scenario
    • 8.8.1.4. Brazil robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory Scenario
    • 8.8.2.3. Competitive Scenario
    • 8.8.2.4. Argentina robotic radiotherapy market, 2021 - 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory Scenario
    • 8.9.1.3. Competitive Scenario
    • 8.9.1.4. South Africa robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory Scenario
    • 8.9.2.3. Competitive Scenario
    • 8.9.2.4. Saudi Arabia robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory Scenario
    • 8.9.3.3. Competitive Scenario
    • 8.9.3.4. UAE robotic radiotherapy market, 2021 - 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory Scenario
    • 8.9.4.3. Competitive Scenario
    • 8.9.4.4. Kuwait robotic radiotherapy market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Profiles
  • 9.3.1. Varian, A Siemens Healthineers Company
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Elekta
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Accuray Incorporated
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. ViewRay Technologies
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. IBA
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Mevion Medical Systems
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Panacea Medical Technologies Pvt. Ltd.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. P-Cure
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. ProNova Solutions, LLC
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Sumitomo Heavy Industries Ltd.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Koninklijke Philips N.V.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. RaySearch Laboratories
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Vision RT Ltd.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. MIM Software Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives